. 2026 Jan 15;31(2):2500275. doi: 10.2807/1560-7917.ES.2026.31.2.2500275

Table 5. Immunisation effectiveness against RSV hospitalisation in children (< 2 years) residing in jurisdictions with population-based nirsevimab programmes, Queensland and Western Australia, Australia, 2024 (n = 800).

Immunisation effectiveness by age	Number of RSV-positive cases		Number of RSV-negative controls		OR	95% CI	aOR	95% CI	Nirsevimab effectiveness	95% CI
Immunisation effectiveness by age	Imm	Unimm	Imm	Unimm	OR	95% CI	aOR	95% CI	Nirsevimab effectiveness	95% CI
RSV hospitalisation
< 6 months	26	108	34	56	0.397	0.217 to 0.725	0.191^a	0.071 to 0.513	80.9%^a	48.7 to 92.9
< 12 months	37	222	58	99	0.284	0.177 to 0.458	0.169^a	0.087 to 0.326	83.1%^a	67.4 to 91.3
12–23 months	12	305	7	60	0.362	0.139 to 0.944	0.766^a	0.222 to 2.645	23.4%^a	−100 to 77.8
RSV-associated ICU/HDU admission
< 12 months	4	15	9	6	0.177	0.039 to 0.806	0.085^b	0.004 to 1.611	91.5%^b	−61.1 to 99.5

aOR: adjusted odds ratio; CI: confidence interval; HDU: high dependency unit; ICU: intensive care unit; Imm: immunised; OR: odds ratio; RSV: respiratory syncytial virus; Unimm: unimmunised.

^a Adjusted by age group, chronic medical conditions, First Nations status, grouped by week and state.

^b Adjusted by age group, chronic medical conditions, First Nations status, grouped by month and state.

First Nations status included all Aboriginal Australian and Torres Strait Islander people based on self-report on medical records.

Table 5. Immunisation effectiveness against RSV hospitalisation in children (< 2 years) residing in jurisdictions with population-based nirsevimab programmes, Queensland and Western Australia, Australia, 2024 (n = 800).

Table 5. Immunisation effectiveness against RSV hospitalisation in children (< 2 years) residing in jurisdictions with population-based nirsevimab programmes, Queensland and Western Australia, Australia, 2024 (n = 800).